Group One Trading
NKTR icon

Group One Trading’s Nektar Therapeutics NKTR Stock Holding History

Group One Trading’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$428K Buy
5,949
+4,501
+311% +$256K ﹤0.01% 3485
2025
Q4 		$61.2K Sell
1,448
-7,081
-83% -$396K ﹤0.01% 5423
2025
Q3 		$485K Sell
8,529
-84,652
-91% -$2.8M ﹤0.01% 3743
2025
Q2 		$2.41M Buy
93,181
+69,771
+298% +$783K 0.01% 1953
2025
Q1 		$239K Buy
+23,410
New +$306K ﹤0.01% 3840
2024
Q4 		– Sell
-1,809
Closed -$31.9K – 7728
2024
Q3 		$35.3K Sell
1,809
-174
-9% -$3.32K ﹤0.01% 4888
2024
Q2 		$36.9K Buy
1,983
+686
+53% +$14.5K ﹤0.01% 4758
2024
Q1 		$18.2K Buy
+1,297
New +$13.6K ﹤0.01% 5490
2022
Q1 		– Sell
-10,310
Closed -$1.53M – 8459
2021
Q4 		$2.09M Buy
10,310
+402
+4% +$87.2K ﹤0.01% 2552
2021
Q3 		$2.67M Buy
9,908
+960
+11% +$231K ﹤0.01% 2361
2021
Q2 		$2.3M Sell
8,948
-800
-8% -$221K ﹤0.01% 2488
2021
Q1 		$2.92M Sell
9,748
-410
-4% -$128K ﹤0.01% 2064
2020
Q4 		$2.59M Buy
10,158
+360
+4% +$93K ﹤0.01% 1827
2020
Q3 		$2.44M Sell
9,798
-600
-6% -$189K 0.01% 1446
2020
Q2 		$3.61M Buy
10,398
+2,190
+27% +$683K 0.02% 1030
2020
Q1 		$2.2M Sell
8,208
-12,841
-61% -$3.97M 0.02% 979
2019
Q4 		$6.82M Buy
21,049
+2,497
+13% +$724K 0.05% 516
2019
Q3 		$5.07M Buy
18,552
+14,574
+366% +$5.34M 0.04% 563
2019
Q2 		$2.12M Buy
3,978
+1,387
+54% +$695K 0.02% 1032
2019
Q1 		$1.31M Sell
2,591
-2,162
-45% -$1.28M 0.01% 1225
2018
Q4 		$2.34M Sell
4,753
-3,515
-43% -$2.12M 0.02% 929
2018
Q3 		$7.56M Sell
8,268
-7,878
-49% -$6.72M 0.06% 376
2018
Q2 		$11.8M Buy
16,146
+6,864
+74% +$7.91M 0.1% 209
2018
Q1 		$14.8M Buy
9,282
+1,759
+23% +$2.27M 0.15% 131
2017
Q4 		$6.74M Buy
7,523
+5,788
+334% +$3.42M 0.05% 495
2017
Q3 		$625K Sell
1,735
-1,959
-53% -$613K 0.01% 1898
2017
Q2 		$1.08M Buy
3,694
+1,210
+49% +$350K 0.01% 1394
2017
Q1 		$874K Sell
2,484
-1,049
-30% -$236K 0.01% 1432
2016
Q4 		$650K Buy
3,533
+3,144
+808% +$639K 0.01% 1609
2016
Q3 		$100K Buy
389
+143
+58% +$36.8K ﹤0.01% 2924
2016
Q2 		$53K Buy
+246
New +$55K ﹤0.01% 3272
2015
Q4 		– Sell
-671
Closed -$138K – 4961
2015
Q3 		$110K Buy
+671
New +$119K ﹤0.01% 2973
2015
Q2 		– Sell
-2,605
Closed -$448K – 5050
2015
Q1 		$430K Buy
2,605
+302
+13% +$62.1K 0.01% 1725
2014
Q4 		$535K Buy
2,303
+1,459
+173% +$312K 0.01% 1495
2014
Q3 		$153K Sell
844
-3,888
-82% -$744K ﹤0.01% 2606
2014
Q2 		$910K Buy
4,732
+4,603
+3,568% +$814K 0.01% 1204
2014
Q1 		$24K Sell
129
-662
-84% -$131K ﹤0.01% 4127
2013
Q4 		$135K Sell
791
-5,532
-87% -$892K ﹤0.01% 2776
2013
Q3 		$991K Buy
6,323
+4,961
+364% +$917K 0.02% 1029
2013
Q2 		$236K Buy
+1,362
New +$209K 0.01% 2022

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Group One Trading's NKTR Position: Q1 2026 in Review

Group One Trading increased its Nektar Therapeutics (NKTR) stake by 311% in Q1 2026, buying an estimated $256K and bringing the position to 5,949 shares worth $428K. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Group One Trading first reported a position in NKTR in Q2 2013 and has held it in 40 quarters since. The position peaked at $14.8M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Group One Trading held 5,949 shares of Nektar Therapeutics worth $428K as of Q1 2026.
  • Group One Trading bought 4,501 Nektar Therapeutics shares in Q1 2026, an estimated $256K.
  • Nektar Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3485 holding.
  • Group One Trading first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Group One Trading's Nektar Therapeutics position peaked at $14.8M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.